Gerresheimer Rebuffs Takeover Bid, Secures Debt Lifeline in Strategic Pivot

German packaging firm Gerresheimer rejects Silgan's takeover bid and wins crucial debt covenant waivers from creditors, aiming to sell US unit Centor to cut debt.

Shares in German packaging specialist Gerresheimer surged nearly 18% on Friday, closing at €20.82, as the company delivered a one-two punch to its challenges. The Düsseldorf-based firm simultaneously rejected an unsolicited takeover approach from US rival Silgan Holdings and secured a crucial debt covenant waiver from its creditors.

The move by lenders grants the company vital breathing room. Approximately 96% of noteholders agreed to extend the deadline for its audited financial statements for 2025 to the end of September 2026. In a parallel step, banks have suspended key financial covenants linked to its €870 million loan volume until the end of the third quarter. Management now aims to publish the audited figures as early as June.

This creditor reprieve follows intense pressure on Gerresheimer after accounting irregularities and BaFin reprimands came to light last autumn. CFO Wolf Lehmann highlighted the broad support from the company's financial partners, providing near-term planning security.

The strategic recalibration was underscored by the swift rejection of Silgan's advance. While the US company's specific bid price was not officially confirmed, industry insiders point to an offer of €41 per share. This figure represents a premium of almost 100% over the recent Xetra trading price around €21. The firm's leadership is clearly betting on an independent future.

Central to that future is the planned divestment of its US subsidiary, Centor. The sale process is already running at full speed, with a double-digit number of interested parties currently conducting due diligence. A transaction is targeted for completion this year. The proceeds are urgently needed to reduce net debt and strengthen the group's balance sheet, allowing a renewed focus on its core pharmaceutical packaging business.

Market reaction has been volatile. Despite Friday's powerful rally, which leaves the stock up roughly 21% for the week, the year-to-date performance remains deeply negative with a loss of nearly 25%. The extreme 30-day volatility, exceeding 110%, reflects persistent investor nervousness.

Analysts maintain a cautious stance, with a median price target hovering just above €24 euros. The majority currently advise holding the stock. The coming months demand operational precision. If Gerresheimer can present its audited accounts in June and successfully conclude the Centor sale, fundamental valuation is expected to return to the forefront. For now, the averted insolvency risk and the spurned takeover have given management the runway it sought.